INTRODUCTION
Modified oligodeoxynucleotides which are complementary to viral mRNA were first shown to have inhibitory effects on cells containing Rous sarcoma virus (1, 2) and subsequently on human immunodeficiency (HIV) (3, 4) , herpes simplex (5), vesicular stomatitis virus (VSV) (6, 7) and influenza viruses (8) . Additionally, expression of cellular genes such as the c-myc protooncogene can be inhibited by oligonucleotides complementary to mRNA (9, 10) . Oligonucleotide mediated gene inhibition has been recently reviewed by Stein and Cohen (11) .
Certain HPV types, in particular HPV16 and HPV18, have been implicated as possible causitive agents in the development of cervical cancer. In cervical tumours and cell lines derived from such tumours the HPV DNA is usually integrated into the host genome. Integration predominantly occurs within the viral El or E2 ORFs and is usually accompanied by deletions in this region. The early region protein E7 of oncogenic HPVs such as HPV 16 is sufficient to cooperate with activated ras and fos oncogenes to transform primary rodent cells (12, 13, 14) and can extend the life span of human cervical keratinocytes (15, 16, 17) .
Immortalization of human keratinocytes also requires expression of both the E6 and E7 proteins (18) . The E7 oncoprotein binds to pi05, the product of the retinoblastoma tumour suppressor gene (19) and is also necessary for the maintenance of the transformed phenotype (20) and in addition undergoes serine phosphorylation (21) . The E6 protein is much less well characterised but has been shown in vitro to bind to p53 protein, also the product of a tumour suppressor gene (22) . The selective retention and continued expression of the E6 and E7 ORFs implies a continual functional requirement for these proteins in the proliferation of cervical tumour cells. The involvement of HPVs in cervical cancer has also been recently reviewed (23) .
We have examined the effect of a range of anti-sense S-oligos to the E6/E7 region of HPV 16 on cervical epithelial tumour cell lines either containing (CaSki) or lacking (C33-I) HPV16. The results show that anti-sense S-oligos which overlapped translation initiation sites of either the E6 or E7 ORFs could, at low micromolar concentrations, inhibit proliferation of HPV16-containing cells when compared to cells lacking HPV. The rate of synthesis of E6 and E7 proteins and steady state level of the E7 were not however markedly decreased by oligos which inhibited cell proliferation.
MATERIALS AND METHODS

Synthesis of oligonucleotides
Oligonucleotides were synthesised at the ICRF Biochemical Services Unit at the Clare Hall laboratories using an Applied Biosystems 3O8B synthesizer. Phosphorothioate analogs were synthesized by standard methods (24, 25) and purified by HPLC. The dried oligos were resuspended in sterile water at a concentration of lmM.
Cell culture Cells were maintained in DMEM (Gibco) supplemented with 10% foetal bovine serum. Cell proliferation assays were performed in 24 well plates containing lml of medium. For protein analysis 90mm dishes of 75 -80% confluent cells were used.
Cell proliferation assays 1 X10
5 cells were plated in lml of media in a 24 well culture dish. Oligos were added to the media 24hr later and incubated for a further 24hr. The cells were labelled for 4hr by addition of 3 H-thymidine at a final concentration of 10/xCi/ml. The cells were rinsed twice in phosphate buffered saline (PBS) and lysed by the addition of lml ice cold 5% TCA at 4°C for 30min. The wells were washed twice with ethanol and the DNA dissolved in 300/d of 0.1M NaOH prior to scintillation counting. Assays were performed in triplicate, the results are expressed as the mean +/-one standard deviation.
Nucleic acid hybridizations
Subconfluent dishes of cells were incubated in the presence of 5/tM oligo for 24hr prior to guanidinium/phenol RNA extraction (26) . lOjig of glyoxylated RNA was electrophoresed through 1.4% agarose gels and transferred to a nylon membrane. This was then probed with a random primed (27) HPV16 total genomic DNA fragment.
Analysis of E6 and E7 proteins
For immunoprecipitation analysis cells were grown to 70-80% confluence on 90mm dishes, starved for lhr in medium lacking cysteine supplemented with 10% dialysed serum and then labelled with lmCi S cysteine for either lhr for E7 or 2hr for E6. For phosphate labelling lmCi of P, was added directly to the cells without prior starvation. Oligos were added to the cells at a final concentration of 5/tM 24 hr prior to labelling and were present at all stages during the labelling period. Cells were lysed and proteins extracted and immunoprecipitated with an anti-E6 polyclonal or anti-E7 monoclonal antibodies as described (13, 28) . The proteins were then fractionated on 15% SDS polyacrylamide gels and either subjected to fluorography (29) or transferred to nitrocellulose membranes for western blot analysis.
RESULTS
Inhibition of [
H]-thymidine uptake
Phosphorothioate oligodeoxynucleotides with chain lengths ranging from 18 to 33 bases with sequences complementary to seven different sites within the E6/E7 region of HPV16 were tested for their ability to inhibit cell proliferation at concentrations up to 20/tM as determined by thymidine uptake. The target sites of the oligos were the capped end of the viral RNA (oligos A and B), the initiation regions of the E6 (oligo Q and E7 (oligo F) ORFs, two internally spliced E6 messages (30) E6*I and E6*II (oligos D and E) and an oligo internal to the E7 ORF (oligo G). The nonsense oligo used (H) had the same chain length and base composition as oligo F. The locations and sequences of the oligos are shown in Figure 1 . The effects of these oligos on CaSki cells, which contain many integrated copies of the HPV16 genome is shown in Figure 2a . Oligo F showed the greatest inhibitory effect by decreasing cell proliferation by 75% at 1/iM and by over 90% at 20/iM. Oligo B was almost as effective as oligo F at 20/iM but was less effective at lower concentrations, decreasing proliferation by about 55% at 1/iM. Oligo C also decreased proliferation by over 90% at 20/iM but was the least effective at 1/iM, decreasing proliferation about 45%. Oligos B and F still showed a marked effect at concentrations below 1/tM. At 0.25/xM oligo F decreased the proliferation of the CaSki cells by about 50%. All the other oligos tested (oligos A,D,E,G,H, Figure 2a ), which included a nonsense sequence (H), decreased proliferation by 20-30% between 1/iM and 20/xM. The observed inhibition was independent of the oligo concentration and may represent a general cytostatic effect of the oligos on the cells. Although the results presented were observed ofter 24hrs, a slight decrease in the proliferation of the CaSki cells was observed after as little as 4hrs exposure to oligo. No significant differences were observed between 24 and 48hrs exposure to oligo. All the oligos were further tested for their ability to inhibit proliferation of C33-I cells, an HPV16 negative cervical epithelial cell line. Unlike CaSki cells however, proliferation of the C33-I cells was only slighdy affected by oligos B,C and F at concentrations of around 1/tM. However at higher oligo concentrations oligos B, C and F could inhibit proliferation of C33-I cells by up to about 60% at 20/tM. Thus at 1/xM oligo F had about a three fold greater effect on CaSki than on C33-I cells (Figure 2b ). The oligos which had no effect on the CaSki cells were also found to be inactive against C33-I cells.
In addition to the oligos described above, we also synthesised oligos equivalent to B, C and F against HPV18 sequences and tested their inhibitory effect against HeLa cells (containing HPV18 DNA) and C33-I cells. We also tested the effects of the anti-HPV16 oligos on HeLa cells, and the anti-HPV18 oligos on CaSki cells. The anti-HPV18 oligos were more effective against HeLa compared to C33-I cells, displaying the same pattern of inhibition on these cells as the anti-HPV16 oligos against CaSki and C33-I cells. Furthermore, the anti-HPV18 were found to inhibit CaSki proliferation to the same degree as the anti-HPV16 oligos, and likewise the anti-HPV16 oligos inhibited HeLa cells indicating that they were not type specific (data not shown).
In addition to phosphorothioate oligos, sequences which were ummodified, contained only one phosphorothioate linkage at the 3' end, or O-methylphosphonate oligos were also tested. The Soligos which contained only one phosphorothioate linkage showed a similar pattern of inhibition to those which were composed entirely of phosphorothioate linkages, although to a much lesser degree suggesting that they were not completely nuclease resistant. Unmodified sequences or O-methylphosphonate oligos had no effect on CaSki cell proliferation (data not shown).
Effect on HPV mRNA by anti sense S-oligos
The oligos which were found to decrease the proliferation of CaSki cells were tested for their ability to decrease HPV16-specific early region transcripts. CaSki cells were incubated with either oligo B,C, or F, or the nonsense oligo H at 5/iM for 24 hours. Total cellular RNA was isolated and subjected to northern blot analysis using an HPV 16 probe. Figure 3 shows that the level of HPV 16 specific transcripts was not significantly altered in the presence of anti-sense oligos, with only a slight reduction caused by the anti-E7 oligo.
Analysis of E6 and E7 proteins in cells exposed to anti-sense oligos
We were interested to determine whether the decrease in the proliferation of the CaSki cells was due to a decrease in the level of the HPV 16 E7 protein, since E7 is known to stimulate DNA synthesis in transformed lines (31) . CaSki cells were incubated with the oligos which were found to inhibit cell proliferation. The E7 protein was extracted (13) and the level was analysed by several different methods. We first asked if the steady state level of E7 protein was decreased by the presence of the antisense oligos. For western blotting the CaSki cells were incubated for 24hrs with the different oligos at 5/iM, since this concentration was the lowest which consistently exerted a maximal effect on cell proliferation. The E7 protein was extracted and then immunoprecipitated with a mixture of the anti-HPV16 E7 monoclonal antibodies 3B, 7B and 10F, separated on a 15% polyacrylamide gel and transferred to a Hybond-C membrane (Amersham International pic, U.K.) which was then reacted with a combination of three anti-E7 monoclonals, 4F, 6D and 8F (32) , and then processed as described. The steady state level of E7 protein was found not to be decreased by the presence of either oligos C, F or H (Figure 4) . We then asked if the rate of synthesis of the E6 or the E7 proteins were decreased by the anti-sense oligos. The E6 or E7 proteins were immunoprecipitated from CaSki cells which had been exposed to S-oligo as before and labelled with lmCi 35 S cysteine. The oligos were present during both the cysteine-free preincubation and cysteine labelling. Oligos F and H both failed to inhibit de novo E6 synthesis, but oligo C caused a slight reduction in E6 synthesis ( Figure 5 ). In contrast to to rate of E6 synthesis, the de novo rate of E7 synthesis is markedly reduced in the presence of any of the oligos tested ( Figure 6 ). Oligos B, C or F appeared to decrease the level of E7 synthesis to a greater extent than the nonsense oligo H (Figure 6 ). Although the level of E7 protein is not grossly affected by any of the oligos tested. However, the E7 protein undergoes serine phosphorylation and it is possible that phosphorylation of the protein could be affected. To investigate this possibilty the CaSki cells were incubated with oligo as before and then labelled directly with lmCi ^Pj without prior starvation, followed by immunoprecipitation and western transfer of E7. Figure 7 shows that the oligo which overlaps the E7 initiation region (oligo F), when compared to oligos C or H, decreased the level of phosphorylation of E7 protein to a greater extent. However, cells incubated with any of the S-oligos displayed an overall decrease in protein synthesis and phosphorylation when compared to untreated cells.
Effect of the oligos on cell growth
The effects of oligos B,C,F and H on cell numbers was monitired over a three day period at both 1/tM and 5/iM on CaSki and C33-I cells and compared to cells not exposed to oligo. The results are presented in figure 8 . Each of the oligos caused a reduction in cell numbers after 24hrs in both the CaSki (panels A and B) and C33-I lines (panels C and D) when compared to cells not exposed to oligo. After 3 days a marked reduction in CaSki cell numbers was observed, which appeared to be independent of which oligo was used.
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Comparison of oligos with nucleic acid databases
Since our tested oligos inhibited cell proliferation without any apparent reduction in the levels of the E6 or E7 proteins we decided to compare the sequences of the inhibitory oligos to the EMBL mammalian nucleic acid databases to determine if they showed any homology to cellular genes. Oligo B had many homologies with 15 (78%) or 16 (84%) residues out of 19 showing complete identity. Interestingly, these sequences included the human somatic cytochrome c gene and pseudogene families and the c-jun proto oncogene. Homologous sequences to oligo C included bovine (17 out of 21, 80%), rat and rabbit protein kinase C genes (16 out of 21, 76%), and the human progesterone receptor and rat glucocorticoid receptors (76%). However it remains to be determined which cellular genes or proteins are affected by these oligos. Sequences with the same degree of homology were also found for oligo F but specific groups of genes could not be identified. Oligos which could inhibit cell proliferation at low yM concentrations (oligos B, C and F) showed greater degrees of homology to other sequences than the other oligos. Using a cut off score of 16 out of 21 residues, oligos C and F were homologous to 0.317% and 0.138% of the data base sequences whilst oligo H identified only 0.040% of the sequences. At cut off scores of 15/19 for oligo B and 17/22 for oligo A 0.074% and 0.069% respectively of the sequences showed homology.
DISCUSSION
During the past few years there has been great interest in the use of antisense oligonucleotides as modulators of gene expression. The mechanisms of action of these compounds is as yet unclear but may include the activation of a cellular RNase H activity acting to cleave the mRNA strand of an RNA:DNA duplex (33), or by translation arrest. Nonsense oligos directed against HIV may either have no effect, or be one of the most effective sequences tested in cellular assay systems (34) . Oligos directed against translation initiation sites of VSV (7) and the ras oncogene (35) , have proved to be particularly useful. In this study we report the effects of a number of such antisense sequences directed against HPV mRNA. Three of these oligos overlap translation start sites of the early region genes E6 and E7, both of which are known to be important for the immortalization of primary human cervical keratinocytes. Two of the other oligos are directed against splice donor and acceptor sites of two potentially different shorter E6 proteins, termed E6*I and E6*H. The longest oligo of chain length 33 (oligo G) is complementary to the DNA sequence at the base of a zinc binding cysteine loop within the E7 protein.
The oligos which overlapped the E6 and E7 start sites are shown to have the greatest effect on cell proliferation. They were able to exert an effect at much lower micromolar concentrations, typically in the range of 1 to 5jiM, when compared to the levels required to have an effect in other systems. In the case of HTV, phosphorothioates were active between 4 and 100/tM (34), with VSV methylphosphonates at about 150fiM in VSV-infected mouse L cells (7), whilst a 90% decrease in ras protein in ras transformed NTH3T3 cells was observed using 50/iM of an oligo complementary to the first 11 nucleotides (35) . Although certain of the anti-HPV oligos were very effective at decreasing cell proliferation as judged by thymidine uptake, this was not accompanied by a concomittant decrease in the steady state levels of E7 protein in either CaSki or HeLa cells (Figure 4) . A reduced rate of 'E7 synthesis was observed in the presence of oligos, including the nonsense oligo H (Figure 5 ), and phosphorylation of the E7 protein was markedly decreased by the anti-E7 S-oligo (F) when compared to the nonsense or anti-E6 oligos. However both of these oligos reduced E7 phosphorylation which could reflect a general cytostatic effect. This suggests that each oligo may exert its inhibitory effect by interfering with different cellular targets.
In contrast the rate of synthesis of E6 protein was only slightly affected by the anti-E6 S-oligo (Q when compared to other oligos ( Figure 6 ). It is interesting to note that an inhibition of thymidine uptake was only observed using phosphorothioate modified oligos, implying that the observed decrease in cell proliferation was only partly brought about by the oligos specifically inhibiting the production of HPV proteins and that other non-specific inhibition of cell proliferation by the phosphorothioates was also observed. Since some of the S-oligos decreased thymidine incorporation to a greater extent than others, part of the observed inhibition may be due to a decreased rate of thymidine uptake or rate of incorporation into DNA. Similar patterns of inhibition, albeit to a lesser extent, were observed for C33-I cells even though they lack HPV 16 DNA which may further reflect differences in oligo uptake between the two lines.
Computer analysis of the oligos suggests thay they share substantial sequence homology to certain cellular genes. This may account for their marked ability to inhibit cell proliferation, without dramatically reducing synthesis or steady state levels of HPV proteins, although the cellular targets of the inhibitory effect remain to be determined. These results draw into question the use of antisense compounds as modulators of HPV gene function or as possible agents in cervical cancer therapy. oligonucleotides used in this study, Drs. R.W.Tindle and I.H.Frazer for the anti-HPV16 and HPV18 E7 monoclonals and Dr. D.Lowy for the anti-HPV 16 E6 serum.
